v3.26.1
Financial Assets - Non current financial assets (Details)
€ in Millions, $ in Millions
12 Months Ended
Dec. 31, 2025
EUR (€)
Dec. 31, 2024
EUR (€)
Dec. 31, 2023
EUR (€)
[1]
Dec. 31, 2025
USD ($)
Dec. 31, 2025
¥ / shares
Dec. 31, 2024
¥ / shares
Disclosure of transactions between related parties [line items]            
Other non-current investments € 339 € 422        
Non-current derivatives   1        
Total Non-current financial assets measured at fair value 339 423        
Non-current guarantee deposits 16 9        
Other non-current financial assets 24 38        
Non-current loans 133 20        
Total Non-current financial assets measured at amortized cost 173 67        
Total non-current financial assets 512 490        
Pledged deposit amounting | $       $ 10    
Maximum exposure to credit risk 2,127 2,472        
Other comprehensive income from financial instruments valuation (98) (18)        
Other comprehensive income, net of tax, gains (losses) from investments in equity instruments (80) (18)        
Other comprehensive income, before tax, gains (losses) from investments in equity instruments € (80) (18) € 0      
Grifols Egypt Plasma Derivatives S.A.E.            
Disclosure of transactions between related parties [line items]            
Maximum exposure to credit risk | $       $ 50    
Shanghai RAAS Blood Products Co., Ltd.            
Disclosure of transactions between related parties [line items]            
Percentage of interest in SRAAS remaining 6.58%     6.58%    
Share price | ¥ / shares         ¥ 6.34 ¥ 7.22
Fair value of financial assets € 336 416        
Other comprehensive income, net of tax, gains (losses) from investments in equity instruments (80) (18)        
Other related parties            
Disclosure of transactions between related parties [line items]            
Guarantee deposits € 1 € 1        
[1] (See Note 2.d)